Antagonism of tumor necrosis factor-alpha (TNF-alpha) may be a good treatment strategy to counter the deleterious effects of TNF-alpha on the development of insulin resistance and the pathogenesis of type 2 diabetes.
Antagonism of tumor necrosis factor-alpha (TNF-alpha) may be a good treatment strategy to counter the deleterious effects of TNF-alpha on the development of insulin resistance and the pathogenesis of type 2 diabetes (T2D), according to a review in the Journal of Cellular Biochemistry by Muhammad Sajid Hamid Akash, PhD, and colleagues.
The review describes the fact that TNF-alpha, one of the most significant pro-inflammatory mediators, induces inflammation in vital organs and has been shown, along with other pro-inflammatory mediators, to become abnormally high in insulin-resistant and T2D experimental animal models and patients. TNF-alpha is interdependently involved in inducing tissue-specific inflammation that may lead to the development of insulin resistance and T2D, and its increased production in adipose tissues is also thought to be related to the obesity-associated insulin resistance that leads to the development of T2D. In addition, TNF-alpha has been shown to impair the beta-cells of pancreatic islet cells, the review notes.
Research has been conducted into anti—TNF-alpha (anti-TNF) treatment strategies in animal models to assess their ability to neutralize TNF-alpha and counter the development of insulin resistance. Some clinical studies of anti-TNF treatment strategies have also been conducted, including one published in Cutis in 2016 by Nawaf Al-Mutairi, MD, and Dalia Shabaan, MD, which showed a beneficial effect of anti-TNF agents on insulin resistance and insulin sensitivity in patients with both psoriasis and T2D.
The authors of the Cutis article note that psoriasis is known to be associated with an increased incidence of insulin resistance and T2D, and it is thought that psoriasis predisposes patients to insulin resistance and may put them at risk for developing T2D.
In their study of 35 psoriasis patients in Kuwait, patients were treated with the anti-TNF agents etanercept, adalimumab, or infliximab for 24 weeks. The study group (patients who received anti-TNF drugs) showed significant improvements in glycemic control as assessed by levels of fasting plasma glucose (FPG) and hemoglobin A1C (HbA1c) at the end of the study, with no significant differences between patients taking any of the 3 anti-TNF medications.
However, patients in the control group showed no significant changes in FPG and HbA1C. The improvement in glycemic control between the control group and the treatment group taking anti-TNF medications was significant. The authors concluded that the results of their study may support a hypothesis that long-term use of anti-TNF agents reduces the mechanisms involved in the development of T2D in patients with psoriasis, and may in turn decrease the coronary artery disease risk in these patients.
Additional large, prospective, multi-center studies are needed to further analyze the effects of anti-TNF antibodies on insulin sensitivity and beta-cell function in insulin-resistant or diabetic patients with psoriasis.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
February 29th 2024In its annual biosimilars report, Cardinal Health provided updates on how provider acceptance growth, evolving payer dynamics, and the growing pipeline for biosimilars will shape the biosimilar landscape over the next 5 years.
Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care
February 16th 2024Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.